Read news from:
Austria
SHARE
COPY LINK

LIFESTYLE

The best cities in France to live in (if jobs and buying property are all that matter)

If you want a decent job and to buy a property without becoming bankrupt, then you should think about moving to some of France's smaller cities, a new study claims.

Published: 17 October 2017 13:09 CEST
The best cities in France to live in (if jobs and buying property are all that matter)
Lille is the most attractive city in France to settle down in according to the survey. Photo: AFP
Have you often wondered which city in France would be the best to live in when based on finding a decent job and being able to buy a property?
 
A new survey claims to have the answer and it lies in France's smaller regional cities.
 
Lille is the most attractive city in France when it comes to getting one of those much-coveted CDIs (permanent jobs) and buying a home without breaking the bank, according to a new survey revealed by Europe 1.
 
That result might surprise many, but not us. Here we explain why we think Lille is “France's most underrated city”. 
 
 
 
Grenoble in the French Alps and Dijon in the Burgundy region of eastern France came second and third in the rankings. The cities of Lyon, Nantes, Toulouse and Rennes were also in the top 10, along with the unfashionable Saint-Etienne, Angers and Le Mans.
 
Comparing France's 20 largest cities, jobs site Joijoba and online property brokers meilleurtaux.com sifted through the job markets, average salaries, property prices and interest rates.
 
The cities were then ranked on these criteria and awarded a score reached by multiplying the number of “affordable” square metres by the chances of securing a permanent job (see below).   
 
 
 
Based on the median salary (the midpoint of the salaries, rather than the average) of each city, the study calculated how much living space could be realistically bought.
 
In Grenoble, where that figure falls on €35,600, the study found that people can afford to live in an apartment of 66 square metres. In Dijon the median salary of €35,000 will get you an even bigger apartment of 73 square metres, however the job market in the eastern French city is slightly less dynamic.
 
In Lille you'd be able to get your hands on a 57 square metre apartment, although the survey did not include what the median salary was in the northern French city.
 
It did say however that with 2.3 permanent job offers per 100 residents, Lille comes second highest in terms of job opportunities nationally. 
 
And while it might come as a shock to many that the northern industrial city of Lille has been deemed the most attractive city to settle down in in France, it's unlikely to surprise anyone that Paris doesn't make top of the list, given the price of property.
 
Paris came in at 15th on the list, a city known for its pokey apartments, people earning the median salary of €49,200 can afford to buy just 24 square metres.
 
 
READ ALSO:

Grenoble, the second most attractive city to live in France when it comes to jobs and buying property. Photo: Vinicius Pinheiro/Flickr
 
Many may be surprised that for once Bordeaux – often cited as the most attractive city to live in France – doesn't top a table of the best place to live in France.
 
In fact, the southwestern city, apparently much-loved by Parisians desperate to leave the capital, came in just 11th out of 20 due a boom in property prices which ahs not been matched by a rise in salaries. 
 
This now means that with the median annual salary of €35,300 euros, it's only possible to buy an apartment of 38 square metres. 
 
It wasn't good news for the southern French city of Marseille either, which came in bottom of the list, largely due to the difficulty people have in finding a job.
 
But what if jobs and property were not all that mattered? The Local's own study on the best places to live in France for foreigners found that Rennes was the place to be. This was based on a whole list of criteria, including regional accents, international airports and proximity to national parks.
 
READ ALSO:

 

Why Rennes is the best city in France for expats to live

 

FEATURE

What does Johnson & Johnson’s delayed vaccine rollout mean for Norway?

Norway has ordered over a million doses of the Johnson & Johnson vaccine as part of its overarching target of offering everyone over the age of 18 a vaccine by July.

Published: 14 April 2021 17:02 CEST
What does Johnson & Johnson’s delayed vaccine rollout mean for Norway?
(Photo by Frederic J. BROWN / AFP)

Vaccination is meanwhile one of the three key criteria authorities in the country say they will  assess before lifting measures.

READ ALSO: 

With the European rollout of the Johnson & Johnson vaccine now delayed, how is Norway’s road out of the pandemic affected?

Why it is delayed

Pharmaceutical company Johnson & Johnson is delaying the rollout of its single use Janssen vaccine in Europe due to concerns over rare potential side effects detected in the United States.

The suspected symptoms include blood clots combined with low platelets in persons who have received the vaccine, according to the company.

“We have taken the decision to proactively delay the rollout of our vaccine in Europe,” Johnson & Johnson said in a statement.

“We have been working closely with medical experts and health authorities, and we strongly support the open communication of this information to healthcare professionals and the public,” it added.

According to the company, the United States Centre for Disease Control and the Food and Drug Administration are reviewing six reported cases in of severe potential side effects that have occurred out of more than 6.8 million doses administered.

Norway’s plan for the vaccine

The Johnson & Johnson vaccine was set to play a vital role in Norway’s aim to offer everyone over the age 18 a vaccine by mid-July.

Norway had ordered over a million vaccines in total. 52,000 doses were set to arrive in April, with a million more coming in June.

The vaccine was to be used primarily to vaccinate people aged between 18-44.

“For many in the age group, this (first dose) will probably be the last dose, because we plan to use the Janssen vaccine from Johnson & Johnson on this group,” director of infection control at the Norwegian Institute of Public Health Geir Bukholm previously told broadcaster NRK.

The vaccine is 66.9 percent effective against moderate symptomatic cases of Covid-19 and 85 percent effective against severe risk of hospitalisation, according to the World Health Organisation.

It would therefore make sense to have used the vaccine on groups with a lower risk of developing severe cases of Covid-19.

How will the delay affect Norway’s vaccination program?

Norway’s programme for vaccinating its population faces a setback with potential delays of 8-12 weeks if the country decides it will no longer use the Janssen vaccine and also chooses not to reimplement the AstraZeneca vaccine, which remains suspended, also due to concerns over potential side effects.

The estimate, which could see everyone over the age of 18 in Norway being offered a vaccine by October, rather than July, was given by department director at the Norwegian Institute for Public Health (NIPH), Line Vold.

“If both AstraZeneca and Johnson & Johnson are excluded, vaccination can be completed 8-12 weeks later provided other vaccines are delivered,” Vold said on Tuesday.

The vaccine schedule should now be changed with vaccines being distributed to areas of high infection as well as introducing a longer interval between doses, according to an expert.

“One measure is that there will be a longer distance in the time between dose one and dose two. The second is a strong skewed distribution geographically,” Steiner Holden, an economics professor who assesses the socio-economic impact of the pandemic  told NRK.

Health minister Bent Høie, however, is still optimistic about Norway’s current vaccination program.

“We see that with the two vaccines we are using (Moderna and Pfizer), we are now vaccinating a significant amount and the supply of the two vaccines will increase in the future,” Høies told NRK.

How will the delay affect Norway’ plan to reopen?

Norway has a four-step plan to reopen society and before each step government will assess three criteria before moving to the next phase of the plan.

The criteria are:

  1. Infection situation and infection rates
  2. Capacity within the health service
  3. Vaccination

Norway will enter phase one on April 16th. The delay of Johnson & Johnson’s rollout in Europe will not affect the country embarking on the first step.

Nor will it currently affect the second step, which could take place in May, according to Prime Minister Erna Solberg.

“For the reopening going forward, there are still three parameters we must consider, and the vaccines are one of them. The bulk of the Janssen vaccine would arrive in June, so for the next step in May, it will be less important,” she said at a government briefing.

However, any delay with the vaccination program will put a much larger burden on the other checkpoints being met.

“But it is important we finish the vaccination program; we must be clear about that. Until then is even more important that we achieve results on the other two parameters, the infection situation and the capacity in the health care system. The fewer vaccinated, the more important the other parameters become in reopening further;” Solberg said.

SHOW COMMENTS